Basit öğe kaydını göster

dc.contributor.authorYoldaş İlktaç, Havvanur
dc.contributor.authorKızıltan, Gül
dc.contributor.authorLanpir, Aslı Devrim
dc.contributor.authorOzansoy, Mehmet
dc.contributor.authorGünal, Mehmet Yalçın
dc.contributor.authorÖzmen Togay, Sine
dc.contributor.authorKeskin, İlknur
dc.contributor.authorÖzdemir, Ekrem M.
dc.contributor.authorKılıç, Ulkan
dc.date.accessioned2022-09-12T10:30:40Z
dc.date.available2022-09-12T10:30:40Z
dc.date.issued2022en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12868/1557
dc.description.abstractWe published the abovementioned article about probiotic mixture VSL#3 on October 6, 2021. Since the product was named VSL#3 in our purchasing process in early 2016, it is referred to as VSL#3 in our article. In addition, the product currently known as VSL#3 is not the same as De Simone Formulation. De Simone Formulation is now available as Visbiome® in the United States and Vivomixx® in Europe. The authors would like to apologise for any inconvenience causeden_US
dc.language.isoengen_US
dc.relation.isversionof10.3409/fb_70-1.05en_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCytokinesen_US
dc.subjectProbioticen_US
dc.subjectOmega-3 fatty aciden_US
dc.subjectInflammatory bowel diseasesen_US
dc.subjectColitisen_US
dc.titleCombined therapy with probiotic VSL#3 and omega-3 fatty acids attenuates colonic injury and inflammation in chronic DNBS-induced colitis in mice (vol 69, pg 135, 2021)en_US
dc.typearticleen_US
dc.contributor.departmentALKÜ, Fakülteler, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.identifier.volume70en_US
dc.identifier.issue1en_US
dc.identifier.startpage43en_US
dc.identifier.endpage43en_US
dc.relation.journalFolia Biologica-Krakowen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Bu öğenin dosyaları:

Thumbnail

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster